Cargando…
The Coronavirus pandemic – 2022: Viruses, variants & vaccines
Since the beginning of the COVID-19 pandemic in 2019–2020, Cytokine & Growth Factor Reviews has published several Special Issues focused on the biology, pathogenesis and therapeutic options in the treatment of COVID-19 infection, including articles on the involvement of the chemokine system in t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8839804/ https://www.ncbi.nlm.nih.gov/pubmed/35216872 http://dx.doi.org/10.1016/j.cytogfr.2022.02.002 |
_version_ | 1784650461207330816 |
---|---|
author | Alexandridi, Magdalini Mazej, Julija Palermo, Enrico Hiscott, John |
author_facet | Alexandridi, Magdalini Mazej, Julija Palermo, Enrico Hiscott, John |
author_sort | Alexandridi, Magdalini |
collection | PubMed |
description | Since the beginning of the COVID-19 pandemic in 2019–2020, Cytokine & Growth Factor Reviews has published several Special Issues focused on the biology, pathogenesis and therapeutic options in the treatment of COVID-19 infection, including articles on the involvement of the chemokine system in the cytokine storm in COVID-19, intervention in the early stages of COVID-19 pneumonia, the therapeutic value of corticosteroid treatment, early clinical intervention with type 1 interferons, progress in vaccine development, and organ specific complications of COVID-19. By 2022, multiple highly efficacious vaccines are available and are being administered in countries around the world, therapeutic options have been clinically evaluated and approved, and SARS-CoV-2 has arguably become the most thoroughly studied virus in history. But, with progress has also come unanticipated problems – misinformation, anti-vaxxers, opposition to protective masks, and politically motivated interference disguised as knowledge. With this issue of CGFR, we continue to document the global coronavirus pandemic and provide an update on the emergence of viral variants, the global effort to administer vaccines and the impediments to progress posed by misinformation and anti-vaccine sentiment. |
format | Online Article Text |
id | pubmed-8839804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88398042022-02-14 The Coronavirus pandemic – 2022: Viruses, variants & vaccines Alexandridi, Magdalini Mazej, Julija Palermo, Enrico Hiscott, John Cytokine Growth Factor Rev Article Since the beginning of the COVID-19 pandemic in 2019–2020, Cytokine & Growth Factor Reviews has published several Special Issues focused on the biology, pathogenesis and therapeutic options in the treatment of COVID-19 infection, including articles on the involvement of the chemokine system in the cytokine storm in COVID-19, intervention in the early stages of COVID-19 pneumonia, the therapeutic value of corticosteroid treatment, early clinical intervention with type 1 interferons, progress in vaccine development, and organ specific complications of COVID-19. By 2022, multiple highly efficacious vaccines are available and are being administered in countries around the world, therapeutic options have been clinically evaluated and approved, and SARS-CoV-2 has arguably become the most thoroughly studied virus in history. But, with progress has also come unanticipated problems – misinformation, anti-vaxxers, opposition to protective masks, and politically motivated interference disguised as knowledge. With this issue of CGFR, we continue to document the global coronavirus pandemic and provide an update on the emergence of viral variants, the global effort to administer vaccines and the impediments to progress posed by misinformation and anti-vaccine sentiment. Elsevier Ltd. 2022-02 2022-02-12 /pmc/articles/PMC8839804/ /pubmed/35216872 http://dx.doi.org/10.1016/j.cytogfr.2022.02.002 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Alexandridi, Magdalini Mazej, Julija Palermo, Enrico Hiscott, John The Coronavirus pandemic – 2022: Viruses, variants & vaccines |
title | The Coronavirus pandemic – 2022: Viruses, variants & vaccines |
title_full | The Coronavirus pandemic – 2022: Viruses, variants & vaccines |
title_fullStr | The Coronavirus pandemic – 2022: Viruses, variants & vaccines |
title_full_unstemmed | The Coronavirus pandemic – 2022: Viruses, variants & vaccines |
title_short | The Coronavirus pandemic – 2022: Viruses, variants & vaccines |
title_sort | coronavirus pandemic – 2022: viruses, variants & vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8839804/ https://www.ncbi.nlm.nih.gov/pubmed/35216872 http://dx.doi.org/10.1016/j.cytogfr.2022.02.002 |
work_keys_str_mv | AT alexandridimagdalini thecoronaviruspandemic2022virusesvariantsvaccines AT mazejjulija thecoronaviruspandemic2022virusesvariantsvaccines AT palermoenrico thecoronaviruspandemic2022virusesvariantsvaccines AT hiscottjohn thecoronaviruspandemic2022virusesvariantsvaccines AT alexandridimagdalini coronaviruspandemic2022virusesvariantsvaccines AT mazejjulija coronaviruspandemic2022virusesvariantsvaccines AT palermoenrico coronaviruspandemic2022virusesvariantsvaccines AT hiscottjohn coronaviruspandemic2022virusesvariantsvaccines |